Who is sponsoring NCT03284619?

NCT03284619 is sponsored by Nucletron Operations BV.

What drugs are being tested in NCT03284619?

Interventions in NCT03284619: Magnetic resonance imager linear accelerator.

What condition does NCT03284619 study?

NCT03284619 studies Bone Metastases.

Is NCT03284619 still recruiting?

NCT03284619 is currently completed. Last updated 29 March 2018.

Last reviewed 2018-03-29 · How we verify

NCT03284619: FIM MR-Linac

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-In Man (FIM) Study MR-Linac

Completed NA Last updated 29 March 2018

What this trial tests

NA trial testing Magnetic resonance imager linear accelerator in Bone Metastases in 5 participants. Completed in 8 September 2017.

Timeline

1 April 2017

Primary endpoint
11 July 2017

8 September 2017

Quick facts

Lead sponsor	Nucletron Operations BV
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	1 April 2017
Primary completion	11 July 2017
Estimated completion	8 September 2017
Sites	1 location across Netherlands

Drugs / interventions tested

Magnetic resonance imager linear accelerator

Conditions studied

Bone Metastases — all drugs for Bone Metastases →

Sponsor

Nucletron Operations BV

Who can join

18 and older, any sex, with Bone Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigational device is the Magnetic resonance imager linear accelerator. Five (5) patients with bone metastases will be treated with palliative intention in this study. The goal is to confirm the pre-clinically demonstrated technical accuracy and safety of the newly developed MR-Linac in the clinical setting.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

MRIgRT head and neck anthropomorphic QA phantom: Design, development, reproducibility, and feasibility study.
Steinmann A, Alvarez P, Lee H, Court L, et al · · 2020 · cited 11× · PMID 31808949 · DOI 10.1002/mp.13951

Verify or expand the search:

Other recruiting trials for Bone Metastases

Currently open trials in the same condition.

NCT06713941 — Management of Bone Metastases · active not recruiting
NCT06392217 — clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases · recruiting
NCT06065449 — A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation T · Phase 3 · recruiting
NCT06487013 — Effectiveness and Safety of ArcBlate Palliative Treatment for Patients With Painful Bone Metastases: A Pivotal Study · NA · recruiting
NCT06189079 — Arterial Embolization for the Treatment of Bone Metastases: Prospective Observational Study · recruiting

Other Nucletron Operations BV trials

Trials by the same sponsor.

NCT03958357 — Post Market Clinical Follow-up Study Venezia · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03284619 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nucletron Operations BV
Last refreshed: 29 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03284619.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing